HER2, HER3, and TROP2: An Update on Novel Treatments for Key Targets

Review the latest evidence on the optimal use of HER2 HER3 and TROP2 antibody&ndash drug conjugates in breast gastrointestinal and lung cancers with an expert commentary plus a webcast with downloadable slides.

Share

Program Content

Activities

HER2, HER3, TROP2 in Breast Cancer
Targeting HER2, TROP2 and HER3: Spotlight on Breast Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: April 08, 2022

Expires: April 07, 2023

HER2 and TROP2 in GI Cancer
Focus on HER2 and TROP2 in Gastrointestinal Cancers
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: April 08, 2022

Expires: April 07, 2023

ADCs in Lung Cancer
Antibody–Drug Conjugates in Lung Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: April 08, 2022

Expires: April 07, 2023

No activities added yet

Activities

ADCs and Biomarkers
Update on ADCs and Biomarkers in Breast, Gastrointestinal, and Lung Cancers
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2022

Expires: June 07, 2023

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.